Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum

Kenneth D Hatch, B. J. Bart, R. C. Hansen, L. E. Millikan, R. C. Reichman, B. Berman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of interferon-alpha2 in the treatment of condyloma acuminatum was conducted enrolling 114 patients. A single wart on each patient was injected with .01 ml 106 units interferon, 105 units interferon, or a placebo, three times weekly for three weeks and then followed for an additional nine weeks. Efficacy was evaluated by measuring change in size and overall change in disease status of the test wart relative to initial condition. In the high-dose treatment group, the mean percent improvement in lesion size was 70.9% at 12 weeks versus 22.5% and 16.7% for low-dose interferon and placebo, respectively (p > .05). Complete clearing of the treated wart occurred in 53% of the high-dose interferon group versus 10% and 14% of the low-dose interferon and placebo groups, respectively (p > .01). Adverse reactions were mild and limited in duration. Flu-like symptoms were present in 57% of high-dose, 29% of low-dose, and 23% of placebo patients. Alpha2-interferon at a dose of 106 units injected intralesionally three times a week for three weeks was highly efficacious in the treatment of condylomata acuminata with excellent safety.

Original languageEnglish (US)
Pages (from-to)187-196
Number of pages10
JournalColposcopy and Gynecologic Laser Surgery
Volume4
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Condylomata Acuminata
Interferons
Placebos
Warts
Therapeutics
Safety

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Hatch, K. D., Bart, B. J., Hansen, R. C., Millikan, L. E., Reichman, R. C., & Berman, B. (1988). Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum. Colposcopy and Gynecologic Laser Surgery, 4(3), 187-196.

Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum. / Hatch, Kenneth D; Bart, B. J.; Hansen, R. C.; Millikan, L. E.; Reichman, R. C.; Berman, B.

In: Colposcopy and Gynecologic Laser Surgery, Vol. 4, No. 3, 1988, p. 187-196.

Research output: Contribution to journalArticle

Hatch, KD, Bart, BJ, Hansen, RC, Millikan, LE, Reichman, RC & Berman, B 1988, 'Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum', Colposcopy and Gynecologic Laser Surgery, vol. 4, no. 3, pp. 187-196.
Hatch, Kenneth D ; Bart, B. J. ; Hansen, R. C. ; Millikan, L. E. ; Reichman, R. C. ; Berman, B. / Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum. In: Colposcopy and Gynecologic Laser Surgery. 1988 ; Vol. 4, No. 3. pp. 187-196.
@article{350021ecc6ad474fba36750f4f46d98a,
title = "Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum",
abstract = "A multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of interferon-alpha2 in the treatment of condyloma acuminatum was conducted enrolling 114 patients. A single wart on each patient was injected with .01 ml 106 units interferon, 105 units interferon, or a placebo, three times weekly for three weeks and then followed for an additional nine weeks. Efficacy was evaluated by measuring change in size and overall change in disease status of the test wart relative to initial condition. In the high-dose treatment group, the mean percent improvement in lesion size was 70.9{\%} at 12 weeks versus 22.5{\%} and 16.7{\%} for low-dose interferon and placebo, respectively (p > .05). Complete clearing of the treated wart occurred in 53{\%} of the high-dose interferon group versus 10{\%} and 14{\%} of the low-dose interferon and placebo groups, respectively (p > .01). Adverse reactions were mild and limited in duration. Flu-like symptoms were present in 57{\%} of high-dose, 29{\%} of low-dose, and 23{\%} of placebo patients. Alpha2-interferon at a dose of 106 units injected intralesionally three times a week for three weeks was highly efficacious in the treatment of condylomata acuminata with excellent safety.",
author = "Hatch, {Kenneth D} and Bart, {B. J.} and Hansen, {R. C.} and Millikan, {L. E.} and Reichman, {R. C.} and B. Berman",
year = "1988",
language = "English (US)",
volume = "4",
pages = "187--196",
journal = "Journal of Gynecologic Surgery",
issn = "1042-4067",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Evaluation of interferon alpha2 (SCH 30500) in the treatment of condyloma acuminatum

AU - Hatch, Kenneth D

AU - Bart, B. J.

AU - Hansen, R. C.

AU - Millikan, L. E.

AU - Reichman, R. C.

AU - Berman, B.

PY - 1988

Y1 - 1988

N2 - A multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of interferon-alpha2 in the treatment of condyloma acuminatum was conducted enrolling 114 patients. A single wart on each patient was injected with .01 ml 106 units interferon, 105 units interferon, or a placebo, three times weekly for three weeks and then followed for an additional nine weeks. Efficacy was evaluated by measuring change in size and overall change in disease status of the test wart relative to initial condition. In the high-dose treatment group, the mean percent improvement in lesion size was 70.9% at 12 weeks versus 22.5% and 16.7% for low-dose interferon and placebo, respectively (p > .05). Complete clearing of the treated wart occurred in 53% of the high-dose interferon group versus 10% and 14% of the low-dose interferon and placebo groups, respectively (p > .01). Adverse reactions were mild and limited in duration. Flu-like symptoms were present in 57% of high-dose, 29% of low-dose, and 23% of placebo patients. Alpha2-interferon at a dose of 106 units injected intralesionally three times a week for three weeks was highly efficacious in the treatment of condylomata acuminata with excellent safety.

AB - A multicenter, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of interferon-alpha2 in the treatment of condyloma acuminatum was conducted enrolling 114 patients. A single wart on each patient was injected with .01 ml 106 units interferon, 105 units interferon, or a placebo, three times weekly for three weeks and then followed for an additional nine weeks. Efficacy was evaluated by measuring change in size and overall change in disease status of the test wart relative to initial condition. In the high-dose treatment group, the mean percent improvement in lesion size was 70.9% at 12 weeks versus 22.5% and 16.7% for low-dose interferon and placebo, respectively (p > .05). Complete clearing of the treated wart occurred in 53% of the high-dose interferon group versus 10% and 14% of the low-dose interferon and placebo groups, respectively (p > .01). Adverse reactions were mild and limited in duration. Flu-like symptoms were present in 57% of high-dose, 29% of low-dose, and 23% of placebo patients. Alpha2-interferon at a dose of 106 units injected intralesionally three times a week for three weeks was highly efficacious in the treatment of condylomata acuminata with excellent safety.

UR - http://www.scopus.com/inward/record.url?scp=0024214763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024214763&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024214763

VL - 4

SP - 187

EP - 196

JO - Journal of Gynecologic Surgery

JF - Journal of Gynecologic Surgery

SN - 1042-4067

IS - 3

ER -